Skip to Content


Active Substance: eptotermin alfa
Common Name: eptotermin alfa
ATC Code: M05BC02
Marketing Authorisation Holder: Olympus Biotech International Limited
Active Substance: eptotermin alfa
Status: Withdrawn
Authorisation Date: 2009-02-19
Therapeutic Area: Spondylolisthesis
Pharmacotherapeutic Group: Drugs for treatment of bone diseases

Therapeutic Indication

Opgenra is indicated for posterolateral lumbar spinal fusion in adult patients with spondylolisthesis where autograft has failed or is contra-indicated.

The marketing authorisation for Opgenra has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.